Collectively, the results herein provide a mechanism-based preclinical and translational rationale, and support a distinct therapeutic opportunity in targeting BAD-mediated survival; and concurrently inhibiting pBADS99 and MEK in KRAS-mutant cancers. This evidence concerns the gene MAP2K7 and cancer.